Join our daily newsletter At The Bell to receive exclusive market insights
- CSL (CSL) appoints Paul McKenzie as its new Chief Executive Officer and Managing Director, effective from March 6
- Dr McKenzie currently holds the position of CSL’s Chief Operating Officer and will immediately join the board of directors as an Executive Director
- The appointment comes with a US$1.75 million (around A$2.6 million) annual salary, along with short- and long-term incentives
- Dr McKenzie succeeds Paul Perreault, who has announced his intention to retire after ten years at the company’s helm and more than 25 years with CSL
- CSL is down 0.65 per cent to $296.27 at 10:36 am AEDT
CSL (CSL) has appointed Paul McKenzie as its new Chief Executive Officer and Managing Director, effective from March 6.
Paul McKenzie currently holds the position of CSL’s Chief Operating Officer and will immediately join the board of directors as an Executive Director.
During his time as COO, he “transformed” CSL’s global end-to-end operations and led CSL Plasma through COVID-19 challenges, while surpassing plasma collection volumes beyond pre-pandemic levels.
He brings with him more than 30 years of leadership experience in the global biotechnology industry, having previously held the roles of Executive Vice President of Pharmaceutical Operations & Technology at Biogen and progressively senior-level roles at Johnson & Johnson and Merck.
“Paul McKenzie is a patient-focused global leader with a demonstrated track record of leading complex organizations and delivering outstanding business results,” CSL Chair Dr Brian McNamee said.
“With his deep understanding of CSL’s strategy, culture and operations, Paul is well-positioned to lead CSL to its next level of sustainable growth for our shareholders and the patients we serve around the world.”
The appointment comes with a US$1.75 million (around A$2.6 million) annual salary with short- and long-term incentives, although he will not be paid any director fees.
Dr McKenzie succeeds Paul Perreault, who has announced his intention to retire after ten years at the company’s helm and more than 25 within the CSL company.
“With Paul at the helm, CSL delivered sustainable growth and innovation with a patient-focused culture,” Dr McNamee said.
“Thanks to Paul’s leadership, CSL today has grown to become a global leader, delivering shareholder value and industry-leading life-saving medicines to people in more than 100 countries.”
Mr Perreault will remain with the company as a strategic adviser to assist in an orderly transition until he retires on September 6, 2023.
CSL was down 0.65 per cent to $296.27 at 10:36 am AEDT.
